Nav: Home

EASL releases editorial response to Cochrane Review of DAAs in HCV

June 28, 2017

GENEVA, Switzerland 28 June 2017 - The European Association for the Study of the Liver (EASL) expresses its serious concerns with the recent publication by the Cochrane Group Review entitled "Direct acting antivirals for chronic hepatitis C" by Jakobsen et al. in which the authors conclude that: "DAAs on the market or under development do not seem to have any effects on risk of serious adverse events [but] we could neither confirm nor reject that DAAs had any clinical effects."

HCV Elimination - A Global Issue

EASL Governing Board Members and Board of Editors at The Journal of Hepatology, state in an editorial response published online today that the Cochrane review could grievously affect policy making and could potentially constrain gathering momentum for an appropriate response to the Global Hepatitis Report from the World Health Organization (WHO). In their report, WHO expresses an alarm at the burden of viral hepatitis, and has promulgated critical targets for global elimination by 2030.

Hepatitis C is found worldwide, and according to WHO, approximately 399 000 people die each year from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma. The negligent and flawed conclusions of the Cochrane review, which could potentially generate unnecessary confusion, serves as a potential barrier, amongst many existing challenges, to HCV elimination.

Cochrane Review's Flawed Analysis

In the editorial, EASL experts explain that, because the complications of chronic hepatitis C take years to occur, depending on the stage of liver disease, and clinical trials with new DAAs with SVR as main endpoint last only a few months, the benefits in terms of clinical outcomes of achieving an SVR cannot be measured in these trials. The primary endpoint in DAA investigational drug development trials has been the SVR, e.g. undetectable HCV RNA 12 or 24 weeks after completion of treatment, reflecting permanent elimination of the viral infection. Once the infection is eliminated (i.e. SVR is achieved), the progression of liver disease is halted or at least considerably slowed down. The trials mentioned in the Cochrane review were not designed or powered to capture long-term outcomes, but to establish whether infection, reflected by a persistent presence of virus in the bloodstream, could be safely and effectively terminated. The Cochrane review displays a serious lack of understanding of hepatitis C and drug development in the context of a transmissible infectious disease with a long natural history.

As a result of their cursory analysis, the EASL editorial found that the Cochrane review overlooked a number of recent studies that showed improvement of quality of life with DAA therapy, demonstrating improved patient-reported outcomes. Subsequently, of grave concern is the Cochrane review authors' conclusion that "randomised clinical trials assessing direct effects of DAA are needed." The editorial goes on to illustrate that such a conclusion suggests an 'ethical anathema' where patients would be left untreated to accumulate increasing hepatic fibrosis, when there are treatments that would likely arrest viral infection, in the overwhelming majority.

"Development of safe and effective treatments for Hepatitis C virus has revolutionised the lives of millions of patients who live with this liver disease. Thousands of investigators around the world have confirmed their effectiveness," said Prof. Rajiv Jalan, Professor of Hepatology at the Royal Free Hospital and Editor-in-Chief of The Journal of Hepatology.

The review, as well as the publicity surrounding it, is drawing a growing body of criticism from experts in the field of hepatology who have respectively outlined the Cochrane review's errors and flawed analysis.

EASL Urges Swift Clarification

Pointing out the slipshod nature of the review, Prof. Jalan added, "The patients and health systems should be reassured that experts consider the recent suggestion that these drugs are ineffective as irresponsible and based on poor interpretation of the available data. With combined, ongoing, world-wide efforts, the deadly Hepatitis C virus can be eradicated and deaths from liver disease reduced."

Prof. Tom Hemming Karlsen, expert hepatologist and Secretary General of EASL echoed this criticism and commented: "The Cochrane analysis is an example of statistics which have gone astray without an expert guide. I quote Sir Austin Bradford Hill from his classic 1965 President's Address to the Royal Society of Medicine: 'Like fire, the chi-squared test is an excellent servant and a bad master.'"

"I am deeply worried that the ill-founded conclusions of the flawed Cochrane analysis might be used to withhold a potentially life-saving antiviral treatment to our patients affected by Hepatitis C," said Prof. Frank Tacke, Vice-Secretary of EASL.

EASL will continue to fight for the global elimination of this viral infection and urges the Cochrane Review authors to issue a corresponding statement to resolve the misconceptions.
-end-
To read EASL editorial "Response to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C", visit: http://www.journal-of-hepatology.eu/content/pressreleases

European Association for the Study of the Liver

Related Hepatitis Articles:

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.
Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.
How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.
New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.
High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.
Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.
How to cure more hepatitis C patients
The cost of cures for hepatitis C have been prohibitive, but experts who served on an NAS panel have a solution that will save more patients and incentivize drug innovation.
Hepatitis C: A novel point-of-care assay
One of the major challenges identified by the WHO in efforts to eradicate the hepatitis C virus is the diagnosis of chronic cases that are generally asymptomatic.
Countries risk 'running out' of hepatitis C patients to treat, says World Hepatitis Alliance
The latest data on the global hepatitis C epidemic, released today at the World Hepatitis Summit in Sao Paulo, Brazil, reveal that most countries (especially high-income countries) are running out of patients to treat because of the low diagnosis rates worldwide.
Australia currently on track to eliminate hepatitis C by 2030, but challenges remain for hepatitis B
New data released at this year's World Hepatitis Summit in Sao Paulo, Brazil, shows that Australia is currently on track to eliminate hepatitis C thanks to its huge efforts to enable population-wide access to treatment.
More Hepatitis News and Hepatitis Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.